- Home
- PRFX vs REVB Comparison
PRFX vs REVB Comparison
Compare PRFX & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- REVB
- Stock Information
- Founded
- PRFX 2007
- REVB 2020
- Country
- PRFX Israel
- REVB United States
- Employees
- PRFX N/A
- REVB N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- PRFX Health Care
- REVB Health Care
- Exchange
- PRFX Nasdaq
- REVB Nasdaq
- Market Cap
- PRFX 2.2M
- REVB 2.3M
- IPO Year
- PRFX 2020
- REVB N/A
- Fundamental
- Price
- PRFX $0.96
- REVB $0.97
- Analyst Decision
- PRFX
- REVB
- Analyst Count
- PRFX 0
- REVB 0
- Target Price
- PRFX N/A
- REVB N/A
- AVG Volume (30 Days)
- PRFX 704.8K
- REVB 118.1K
- Earning Date
- PRFX 11-14-2025
- REVB 11-06-2025
- Dividend Yield
- PRFX N/A
- REVB N/A
- EPS Growth
- PRFX N/A
- REVB N/A
- EPS
- PRFX N/A
- REVB N/A
- Revenue
- PRFX N/A
- REVB N/A
- Revenue This Year
- PRFX N/A
- REVB N/A
- Revenue Next Year
- PRFX N/A
- REVB N/A
- P/E Ratio
- PRFX N/A
- REVB N/A
- Revenue Growth
- PRFX N/A
- REVB N/A
- 52 Week Low
- PRFX $0.88
- REVB $0.96
- 52 Week High
- PRFX $16.63
- REVB $60.48
- Technical
- Relative Strength Index (RSI)
- PRFX 36.20
- REVB 28.79
- Support Level
- PRFX $0.88
- REVB $0.96
- Resistance Level
- PRFX $1.26
- REVB $1.09
- Average True Range (ATR)
- PRFX 0.09
- REVB 0.08
- MACD
- PRFX -0.03
- REVB -0.00
- Stochastic Oscillator
- PRFX 19.60
- REVB 5.24
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).